Cellectis ADR (NASDAQ: CLLS) stock jumped 5.80% on Monday to $3.10 against a previous-day closing price of $2.93. With 0.48 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.81 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $3.1600 whereas the lowest price it dropped to was $2.8210. The 52-week range on CLLS shows that it touched its highest point at $4.04 and its lowest point at $0.96 during that stretch. It currently has a 1-year price target of $8.50. Beta for the stock currently stands at 2.95.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CLLS was up-trending over the past week, with a rise of 23.02%, but this was up by 156.20% over a month. Three-month performance surged to 68.48% while six-month performance rose 72.22%. The stock gained 44.19% in the past year, while it has gained 47.62% so far this year. A look at the trailing 12-month EPS for CLLS yields -1.68 with Next year EPS estimates of -1.25. For the next quarter, that number is -0.28. This implies an EPS growth rate of 38.85% for this year and 12.38% for next year.
Float and Shares Shorts:
At present, 71.58 million CLLS shares are outstanding with a float of 68.77 million shares on hand for trading. On Oct 30, 2023, short shares totaled 0.37 million, which was 0.65% higher than short shares on Sep 28, 2023. In addition to Dr. Andre Choulika Ph.D. as the firm’s Co-Founder, CEO & Director, Dr. David J. D. Sourdive Ph.D. serves as its Deputy CEO, Executive VP of CMC & Manufacturing and Director.
Through their ownership of 28.42% of CLLS’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 9.65% of CLLS, in contrast to 11.31% held by mutual funds. As the largest shareholder in CLLS with 8.07% of the stake, Long Focus Capital Management LLC holds 4,487,293 shares worth 4,487,293. A second-largest stockholder of CLLS, Capital Research & Management Co, holds 1,848,804 shares, controlling over 3.33% of the firm’s shares. Credit Suisse Asset Management is the third largest shareholder in CLLS, holding 1,438,255 shares or 2.59% stake. With a 3.33% stake in CLLS, the American Funds Small Cap World Fu is the largest stakeholder. A total of 1,848,804 shares are owned by the mutual fund manager. The CS Invt. Fds. 2 -, which owns about 2.59% of CLLS stock, is the second-largest Mutual Fund holder. It holds 1,438,255 shares valued at 1.4 million. Principal Funds, Inc. – Small Cap holds 0.95% of the stake in CLLS, owning 528,200 shares worth 0.51 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CLLS since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With CLLS analysts setting a high price target of $14.00 and a low target of $3.00, the average target price over the next 12 months is $8.50. Based on these targets, CLLS could surge 351.61% to reach the target high and fall by -3.23% to reach the target low. Reaching the average price target will result in a growth of 174.19% from current levels.
Summary of Insider Activity:
Insiders traded CLLS stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 1 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 2,186,960 while 0 shares were sold.